# Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer

> **NCT02316002** · PHASE2 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 51 (actual)

## Conditions studied

- Oligometastatic Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02316002
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-21
- **Primary completion:** 2018-09-30
- **Final completion:** 2022-12
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2025-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02316002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02316002, "Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02316002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*